Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive bre...
Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib
About this item
Full title
Author / Creator
Publisher
Springer
Journal title
Language
English
Formats
Publication information
Publisher
Springer
Subjects
More information
Scope and Contents
Contents
Purpose Resistance to HER2 (ErbB2)-targeted therapy may be mediated by other members of the ErbB family. We investigated the efficacy and safety of the irreversible ErbB family blocker, afatinib, alone as first-line therapy in the advanced setting and in combination with vinorelbine or paclitaxel for those who progressed on afatinib monotherapy, in...
Alternative Titles
Full title
Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_gale_healthsolutions_A698653508
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_healthsolutions_A698653508
Other Identifiers
ISSN
0167-6806
